文献速递血栓与止血

美国疾病控制与预防中心凝血因子Ⅷ抑制物检测方法的检测下限与阳性阈值

Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.
PubMed 文献 · J Thromb Haemost · 2017-09-14

研究评估美国疾病控制与预防中心改良Nijmegen-Bethesda法(CDC-NBA)在极低抑制物滴度下的性能,该法含分析前热灭活以释放结合的抗FⅧ抗体。稀释抑制物在0.4 NBU以下呈线性,检测下限为0.2 NBU;IgG4抗FⅧ抗体频率从0.4 NBU的14.3%升至0.5 NBU的67%,验证了≥0.5 NBU的阳性阈值。

要点

  • CDC-NBA可检测低至0.2 NBU的抑制物。
  • IgG4抗FⅧ抗体频率在0.4至0.5 NBU间从14.3%升至67%。
  • 结果支持CDC-NBA采用≥0.5 NBU的阳性阈值。

核心结论

  • CDC-NBA能检测低至0.2 NBU的抑制物,荧光免疫法更敏感,可在部分NBU阴性(<0.5)患者中检出抗FⅧ IgG4。
  • IgG4频率在0.4至0.5 NBU间的急剧增加验证了CDC-NBA的既定阳性阈值≥0.5 NBU,支持需要方法特异性阈值。

研究设计与样本

  • 用CDC-NBA检测已知抑制物的标本,该法包含分析前热灭活以释放结合的抗FⅧ抗体。
  • 用荧光免疫法(FLI)测定IgG4抗FⅧ抗体。

主要发现

  • 稀释抑制物在0.4 Nijmegen-Bethesda单位(NBU)以下呈线性。
  • 用四种统计方法确定CDC-NBA的检测下限为0.2 NBU。
  • IgG4抗FⅧ抗体在滴度≥0.2 NBU的标本中出现率高于健康对照背景率。
  • IgG4抗FⅧ抗体频率从0.4 NBU的14.3%升至既定阳性阈值0.5 NBU的67%。

关键数值与推荐

  • CDC-NBA的检测下限为0.2 NBU。
  • CDC-NBA的既定阳性阈值为≥0.5 NBU。
  • IgG4抗FⅧ抗体频率在0.4 NBU为14.3%,在0.5 NBU为67%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Immunologic methods detect factor VIII (FVIII) antibodies in some inhibitor-negative specimens. Specimens were tested by modified Nijmegen-Bethesda assay (NBA) and fluorescence immunoassay. The NBA with preanalytical heat inactivation detects FVIII inhibitors down to 0.2 NBU. IgG4 frequency validates the established threshold for positivity of ≥ 0.5 NBU for this NBA. SUMMARY: Background The Bethesda assay for measurement of factor VIII inhibitors called for quantification of positive inhibitors by using dilutions producing 25-75% residual activity (RA), corresponding to 0.4-2.0 Bethesda units, with the use of 'more sensitive methods' for samples with RA closer to 100% being recommended. The Nijmegen modification (Nijmegen-Bethesda assay [NBA]) changed the reagents used but not these calculations. Some specimens negative by the NBA have been shown to have FVIII antibodies detectable with sensitive immunologic methods. Objective To examine the performance at very low inhibitor titers of the Centers for Disease Control and Prevention (CDC)-modified NBA (CDC-NBA), which includes preanalytic heat inactivation to liberate bound anti-FVIII antibodies. Methods Specimens with known inhibitors were tested with the CDC-NBA. IgG4 anti-FVIII antibodies were measured by fluorescence immunoassay (FLI). Results Diluted inhibitors showed linearity below 0.4 Nijmegen-Bethesda units (NBU). With four statistical methods, the limit of detection of the CDC-NBA was determined to be 0.2 NBU. IgG4 anti-FVIII antibodies, which correlate most strongly with functional inhibitors, were present at rates above the background rate of healthy controls in specimens with titers ≥ 0.2 NBU and showed an increase in frequency from 14.3% at 0.4 NBU to 67% at the established threshold for positivity of 0.5 NBU. Conclusions The CDC-NBA can detect inhibitors down to 0.2 NBU. The FLI, which is more sensitive, demonstrates anti-FVIII IgG4 in some patients with negative (< 0.5) NBU. The sharp increase in IgG4 frequency between 0.4 and 0.5 NBU validates the established threshold for positivity of ≥ 0.5 NBU for the CDC-NBA, supporting the need for method-specific thresholds.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Miller CH, Boylan B, Shapiro AD, et al. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. J Thromb Haemost. 2017. PMID: 28795528. doi:10.1111/jth.13795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。